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In order to avoid low absorption, incorporation, and undesirable side eﬀects of inorganic oxovanadium compounds, the
antidiabetic activities of organic oxovanadium (IV) compounds in alloxan-induced diabetic mice were investigated. Vanadyl
carboxymethyl carrageenan (VOCCA) and vanadyl carboxymethyl chitosan (VOCCH) were synthesized and administrated
through intragastric administration in diﬀerent doses for 20 days in alloxan-induced diabetic mice. Glibenclamide was
administrated as the positive control. Our results showed that low-dose group, middle-dose group, and high-dose group of
VOCCA and VOCCH could signiﬁcantly reduce the levels of blood glucose (P<0.05) compared with untreated group, but not
in normal mice. Besides, high-dose groups of VOCCA and VOCCH exhibited more signiﬁcant hypoglycemic activities (P<0.01).
After treated with VOCCH, the oral glucose tolerance of high-dose group of VOCCH was improved compared with model control
group (P<0.05).
1.Introduction
Diabetes mellitus (DM), which results from insulin deﬁ-
ciency or insulin resistance, is a serious chronic metabolic
disease [1]. The DM includes insulin-dependent type 1 DM
and non-insulin-dependent type 2 DM. Until now, type 1
DM can only be controlled by subcutaneous injections of
insulin,whichcausesmanyproblemstothepatients.Inorder
to treat type 2 DM, some drugs have also been synthesized
[2], for example, sulfonylureas, sulfonamides, biguanides,
thiozolidinediones, and so on. Orally active therapeutic
agents instead of painful insulin injections for type 1 DM
and synthetic drugs without side eﬀects for type 2 DM have
become an urgent and important requirement.
Vanadium is not only an important trace element for
organisms, but also the necessary element for human body
[3]. It has been demonstrated that many vanadium com-
pounds possess therapeutic eﬀects as insulin mimetics [4, 5].
Heyliger et al. ﬁrst reported the insulin mimetic activity
of oral vanadate in vivo in 1985 [6]. Since then, extensive
studieshavebeencarriedouttoexplorevanadiumchemistry,
including the synthesis of novel complexes and their antidia-
betic activities both in vitro and in vivo [7–16]. Furthermore,
many clinical trials of vanadium compounds have also
been reported [17–20], in which vanadium salts such as
VOSO4 and NaVO3 were administered to diabetic patients.
In order to enhance both lipophilicity and bioavailability
of vanadium compound, overcome the disadvantage of side
eﬀects, increase the half-life of the compound, decrease sys-
temic drug toxicity, improve treatment absorption rates, and
provide protection for pharmaceuticals against biochemical
degradation, two types of less toxic vanadyl (+4 oxidation
state of vanadium) complexes with diﬀerent coordination
structures were synthesized and examined.
In addition, the polysaccharide polymer is biodegradable
and biocompatible and would be eﬀective in enhancing drug
bioavailability through the mechanism of delaying release. In
order to investigate the impact of diﬀerent organic ligands
onvanadylcomplexes,vanadylcarboxymethylk-carrageenin
and vanadyl carboxymethyl chitosan were synthesized. The2 Evidence-Based Complementary and Alternative Medicine
present study was performed to investigate the antidiabetic
properties of these two new vanadyl complexes in alloxan-
induced diabetic mice.
2.MaterialsandMethods
2.1. Materials and Equipments. K-carrageenin and chitosan
with a deacetylation degree of 95.3% were purchased
from Qingdao Baicheng Biochemical Corp (China), their
viscosity-average molecular weights were 3.77 × 105 and
2.0 × 105, respectively. Isopropanol, glucose, alloxan, and
vanadyl sulfate hydrate (VOSO4·xH2O, x = 3t o5 )w e r e
purchased from the Sigma-Aldrich Chemical Co. Gliben-
clamide was purchased from Paciﬁc pharmaceutical technol-
ogy group. Ethanol, sodium hydroxide, and other reagents
were purchased from Sinopharm Co. Kunming mice were
provided by experimental animal center, Kunming. The IR
spectra were measured on a JASCO-4100FT-IR spectrometer
with KBr disks. The content of vanadium is measured on
7AS-986 (G) Atomic Absorption Spectrometer. Chemicals
and solvents were reagent grade.
2.2. Synthesis of VOCCA and VOCCH. K-carrageenin (chi-
tosan) (50g) was added into 750mL isopropanol and stirred
for 30min. 40mL sodium hydroxide solution (mass fraction
is 50%) was slowly dropped into the mixture (25min) and
stirred for 3h. Then 60g monochloroacetic acid was added
into the mixture for 5 times in 30min, and the system
temperature was kept at 60◦C for 4h. After incubating for
4h, the temperature was lowered to 25◦C and the pH was
adjusted to 7.0. The mixture was then concentrated with
ethanol three times in volume of the mother liquid. After
ﬁltration,washing,drying,andsmashing,thecarboxymethyl
carrageenin and carboxymethyl chitosan were obtained.
Ashing method [21] was applied to calculate the SD
of carboxymethyl groups of carboxymethyl carrageenin and
carboxymethyl chitosan. Carboxymethyl carrageenin and
carboxymethyl chitosan were vacuum dried at 60◦Ct oc o n -
stant mass; carboxymethyl carrageenin and carboxymethyl
chitosan were heated and scorched at 700◦C for 15–20min.
T h er e s i d u e sw e r eN a 2O, leached with 50mL HCl solution
(0.1moI/L), heated, and followed by residual titration with
0.1mol/L standard NaOH. The SD of carboxymethyl groups
of carboxymethyl carrageenin and carboxymethyl chitosan
were calculated as the formula discussed by Wang and Ye.
Vanadyl carboxymethyl carrageenin (chitosan) (the SD
of carboxymethyl carrageenin and carboxymethyl chitosan
were 47.3% and 84.9%, resp.) was prepared by mixing
various amounts of VOSO4 with carboxymethyl carrageenin
(themassratioofVtocarboxymethylcarrageenin(chitosan)
was 1%) solutions under magnetic stirring for 24h at room
temperature. Ethanol four times in volume of the mother
liquid was added to the solution to complete precipitation
of vanadyl carboxymethyl carrageenin (chitosan) complex.
The resulting precipitate was washed with ethanol and dried
under a vacuum condition at room temperature, and white
solid vanadyl carboxymethyl carrageenin and carboxymethyl
chitosanwereobtained.VOCCAandVOCCHweredissolved
in tap water to the concentration of 5% (w/v) every day and
kept at 4◦C.
2.3. Vanadium Content Determination. 7AS-986 (G) Atomic
Absorption Spectrometry was applied to determine the
content of vanadium of the complex according to the
standard method of the instruction.
2.4. Maximal Tolerant Dose (MTD) Determination of
VOCCA. Theresultofpreliminaryacutetoxicitytestshowed
no death of mouse. Afterwards, the Maximal Tolerant Dose
(MTD) test was carried out. Twenty normal mice weighing
20 ± 2gwerefastedfor24h,thenV OCCA(5%,0.8mL)was
administered intragastricallythreetimes a day fortwoweeks.
After two weeks, the maximum tolerated dose was calculated
according to the formula:
MTD =
the dose of intragastric administration × 3
body weight of rat
. (1)
2.5.ConstructionofDiabeticMouseModel. Malemiceweigh-
ing 20–24g were used for animal model construction. Mice
were fasted for 24h and then intraperitoneally injected
alloxan (160mg/kg). Five days after alloxan injection, the
mice were fasted for 6h and blood samples were obtained
from tail vein of the mice. The blood glucose levels were
measured by the glucose oxidase method. The alloxan-
injected mice with the blood glucose level between 10 and
20mmol/L were considered as diabetic mice.
2.6. Glucose-Lowering Test. Normal mice and diabetic mice
were randomly divided into 6 groups (10 mice per group).
Normal control group: normal mice; model control group:
diabetic mice treated with tap water; glibenclamide control
group: diabetic mice treated with 0.2g/kg glibenclamide;
low-dose group: diabetic mice treated with 0.3125g/kg
VOCCH and 0.6250g/kg VOCCA; middle-dose group: dia-
betic mice treated with 0.6250g/kg VOCCH and 1.250g/kg
VOCCA; high-dose group: diabetic mice treated with
1.2500g/kg VOCCH and 2.500g/kg VOCCA. The samples
above were administered intragastrically for 20 days.
2.7. Oral Glucose Tolerance Test (OGTT) of VOCCH. After
the VOCCH was administered intragastrically in both nor-
mal and alloxan-induced diabetic mice for 20 days, oral
glucose tolerance test was executed. Glucose loaded with the
single dose of 2.5g/kg was intragastrically administered to
mice fasted for 6h, and the blood glucose level was checked
at 0, 0.5, 2h.
2.8. Blood Sample Collection. The blood samples were
obtained from tail vein of mice. Firstly, the tail of mouse was
put into hot water (50◦C) for several minutes and cleaned,
then the tail tip was cut for 1-2mm long and blood sample
was obtained.
2.9. Statistical Analysis. All data were expressed as the mean
± SD. Statistical analysis was performed by one-way analysisEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: FT-IR spectra of chitosan.
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Figure 2: FT-IR spectra of carboxymethyl chitosan.
of variance (ANOVA) followed by the least signiﬁcant
diﬀerence (LSD) test for the multiple comparisons among
the groups. Values for P<0.05 were considered statistically
signiﬁcant.
3. Result
3.1. Character of VOCCA and VOCCH. Figures 1, 2,a n d
3 are infrared spectra of chitosan, carboxymethyl chi-
tosan, and vanadyl carboxymethyl chitosan. Infrared spec-
trum (Figure 2) showed that C–OH stretching vibration
absorption peak of carboxymethyl chitosan was located at
1066.44cm−1, N–H and O–H at 3408.57cm−1, –OH anti-
symmetrical stretching vibration absorption peak (COO)
was located at 1603.52cm−1, and its symmetrical stretching
vibration (COO) absorption peak was at 1421.28cm−1.
Infrared spectrum of VOCCH (Figure 3) showed that C–
OH absorption peak was displaced to 1070.30cm−1,N – H
and O–H absorption peaks were displaced to 3371.92cm−1,
OH antisymmetrical stretching vibration absorption peak
and its symmetrical stretching vibration (COO) absorption
peak were displaced to 1599.66cm−1 and 1416.46cm−1.
This indicated that carboxyl, amino-group, and hydroxyl
participated in the interaction of carboxymethyl chitosan
and VO2+. The content of V in VOCCH was 0.36%.
Figures 4, 5,a n d6 are the IR spectra of carrageenan,
carboxymethyl carrageenan, and vanadyl carboxymethyl
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Figure 3: FT-IR spectra of vanadyl carboxymethyl chitosan.
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Figure 4: FT-IR spectra of carrageenan.
carrageenan. Compared to the carrageenan, carboxymethyl
carrageenan showed characteristic peak 1610cm−1 of C=O
group. Further, the peak of C=O in carboxymethyl car-
rageenan at 1610cm−1 shift to 1604cm−1 of vanadyl car-
boxymethyl carrageenan, also the shifts of absorption peaks
of S=O and OH were observed (Figure 6). These results
clearly indicated the incorporation of carboxymethyl group
and VO2+ into carrageenan and carboxymethyl carrageenan,
respectively. The content of V of VOCCA measurement on
Atomic Absorption Spectrometry was 0.18%.
3.2. MTD of VOCCA. In the test of maximal tolerant dose,
there were no convulsions, vomiting, or other negative
symptoms.
MTD = 0.8mL×5g/mL ×
3
20
g = 6.0g/Kg. (2)
3.3. Glucose-Lowering Studies and OGTT. In Figures 7 and
8, the body weights of each group before and after treatment
withVOCCAandVOCCHareshown.Inthisstudy,thebody
weights of diabetic mice were lowered compared with those
of normal control mice throughout the experimental period
of 20 days. At the end of the experiment, the body weights of
vanadium-treated groups exhibited no signiﬁcant deviation
with model control group and glibenclamide control group.4 Evidence-Based Complementary and Alternative Medicine
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Figure 5: FT-IR spectra of carboxymethyl carrageenan.
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Figure 6: FT-IR spectra of vanadyl carboxymethyl carrageenan.
The body weight proﬁle indicated that there was no
negativeimpactonbodyweightofthemiceaftertreatedwith
both VOCCA and VOCCH. These complexes showed com-
parable results with other vanadyl coordination compounds
[22].
T h ec h a n g e so fb l o o dg l u c o s el e v e l sa r es h o w ni nT a b l e s
1 and 2. The initial blood glucose levels of the diabetic
mice were similar. Low-dose group, middle-dose group, and
high-dose group of VOCCA could statistically signiﬁcantly
reduce the levels of blood glucose (P<0.05) compared
with model control group, and high-dose group of VOCCA
had more signiﬁcant hypoglycemic activity (P<0.01)
(Table 1). There was no obvious diﬀerence among low-dose
group, middle-dose group, and high-dose group compared
with glibenclamide control group (P>0.05). Low-dose
group, middle-dose group, and high-dose group of VOCCH
could statistically signiﬁcantly reduce the levels of blood
glucose (P<0.05) compared to model control group.
However, high-dose group showed more apparent eﬀect
than glibenclamide control group (P<0.01) (Table 2).
Furthermore, the oral glucose tolerance was improved in
diabetic animals after treated with VOCCH (P<0.05)
(Figure 9). Meanwhile, low-dose group, middle-dose group,
and high-dose group of VOCCA and VOCCH showed no
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Figure 7: Impacts of intragastric VOCCA administration on body
weight in both normal and alloxan-diabetic mice; (A): normal
controlgroup,(B):modelcontrolgroup,(C):glibenclamidecontrol
group, (D): low dose group, (E): middle dose group, (F): high dose
group.
Table 1: Impacts of intragastric VOCCA on blood glucose levels in
both normal and alloxan-diabetic mice.
Group Dose
(g·Kg−1) 0w e e k 3w e e k
Normal control group 0 5.7 ± 0.6 6.0 ± 0.16
Model control group 0 17.8 ± 4.6 32.2 ± 3.3
Glibenclamide
control group 0.2000 17.9 ± 4.3 26.7 ± 2.6
Low-dose group 0.6250 18.0 ± 4.3 28.9 ±4.5ad
Middle-dose group 1.2500 17.8 ± 4.4 28.1 ±5.0ad
High-dose group 2.500 17.6 ± 4.3 25.9 ±4.7ac
aP<0.01, bP<0.05, versus normal control group; cP<0.01, dP<0.05,
versus model control group.
negative inﬂuence on blood glucose levels of normal mice
(Tables 1 and 2).
Among low-dose group, middle-dose group and high-
dose group of VOCCA and VOCCH at the same concentra-
tionofvanadium,thebloodglucoselevelsofVOCCHgroups
reduced from 29.8 (model control group) to 24.2, 22.4, 17.1,
respectively,whileVOCCAgroupsreducedfrom32.2(model
control group) to 28.9, 28.1, and 25.9, respectively, which
indicated that VOCCH would be better candidate as insulin
enhancer than VOCCA.
As shown in Figure 9, the blood glucose concentrations
of mice increased greatly after loading with D-glucose and
then reduced smoothly. In the OGTT test, the blood glucose
concentrations of normal mice remained less than 8mM,
while the model control group was consistently higher than
that of the vanadium-treated groups. The blood glucoseEvidence-Based Complementary and Alternative Medicine 5
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Figure 8: Impacts of intragastric VOCCH administration on body
weight in both normal and alloxan-diabetic mice; (A): normal
controlgroup,(B):modelcontrolgroup,(C):glibenclamidecontrol
group,(D):low-dosegroup,(E):middle-dosegroup,(F):high-dose
group.
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Figure 9: Impacts of VOCCH on glucose tolerance in normal mice
and alloxan-diabetic mice. (A): normal control group, (B): model
control group, (C): glibenclamide control group, (D): low dose
group, (E): middle dose group, (F): high dose group. dP < 0.05,
versus model control group.
levels of diabetic mice remained above the basal levels at the
end of the test. However, the blood glucose concentrations
of vanadium treated groups were signiﬁcantly lower than
model control groups. Furthermore, the results of the OGTT
indicated that impaired glucose tolerance was improved after
treatment with VOCCH.
Table 2: Impacts of intragastric VOCCH on blood glucose levels in
both normal and alloxan-diabetic mice.
Group Dose
(g·Kg−1) 0w e e k 3w e e k
Normal control group 0 5.7 ± 0.6 5.1 ± 0.5
Model control group 0 17.0 ± 4.7 29.8 ± 5.4
Glibenclamide
control group 0.200 17.1 ± 4.5 21.4 ± 4.5
Low-dose group 0.3125 17.6 ± 4.7 24.2 ±3.4ad
Middle-dose group 0.6250 17.5 ± 4.4 22.4 ±5.6ac
High-dose group 1.2500 17.2 ± 4.3 17.1 ±6.9acf
aP<0.01, versus normal control group; cP<0.01, dP<0.05, versus model
control group; fP<0.01, versus glibenclamide control group.
4. Discussion
Insulin-mimetic properties of vanadium salts and vanadium
compounds have been widely reported in both type 1 and
type 2 diabetic animal models [23–25]. Inorganic vanadium
compounds have already been known to be eﬀective in
treatment of diabetic hyperglycemia, but the side eﬀects,
such as vomiting, diarrhea, hepatic, and renal toxicity limit
their application [26, 27]. Organic vanadium coordination
compounds have been proved with better absorption eﬃ-
ciency in gastrointestinal tract [28]. In this study, high doses
of VOCCH and VOCCA exhibited antidiabetic activity at
signiﬁcantly lower intake levels of elemental vanadium com-
pared to glibenclamide. Vomiting and diarrhea, the major
side eﬀects of vanadium compounds, were not observed.
For example, BMOV and similar compounds like bis (ethyl-
maltolato) oxovanadium (IV) (BEOV) have already been in
clinicaltrials[29].However,thetoxicity,lowerbioavailability
and nonlinear pharmacokinetics of these compounds com-
promise their pharmacological success [30]. These results
indicated that the corporation of essential trace element
vanadium and polysaccharide could enhance their biological
activity, intercoordination, and bioavailability. The insulin-
enhancing properties of organic vanadium complexes have
previously been compared with those of inorganic vanadium
salts [31, 32]. It was reported that vanadium-enriched
Cordyceps sinensis wasbeneﬁcialforcontemporarytreatment
ofdepressionanddiabetesthroughthecoeﬀect[33].VOCCA
and VOCCH also may be potential strategies for lowering
the blood sugar level through the coeﬀect of vanadium and
carboxymethyl-carrageenan and carboxymethyl-chitosan. In
the present study, VOCCH, VOCCA, and VOSO4 showed
similar hypoglycemic functions. However, the vanadium
intake amount in the form of VOCCH and VOCCA was
signiﬁcantly lower than that of VOSO4 [22]. These results
indicated that the anti-diabetic abilities of VOCCH and
VOCCA were more eﬀective than VOSO4.
5. Conclusion
A beneﬁcial role of enhancing anti-diabetic actions of
VOCCH and VOCCA was found in this study. VOCCH6 Evidence-Based Complementary and Alternative Medicine
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Figure 10: Schematic presentation of insulin signal transduction
and possible action mechanisms of VOCCH and VOCCA.
and VOCCA would be good candidates of insulin enhancers
to eﬀectively activate glucose metabolism in vivo and reg-
ulate glucose metabolism by inﬂuencing insulin levels. The
ligands of carboxymethyl carrageenin and carboxymethyl
chitosan allowed vanadium to supply at the minimal doses,
prolonged the duration of drug activity, and reduced the
toxicity of vanadium. This implied that carboxymethyl
carrageeninandcarboxymethylchitosanwouldbepromising
biocompatible and biodegradable vehicles for the delivery of
VO2+ ions.
Insulin receptor which is a kind of transmembrane gly-
coprotein complex molecules consists of two alpha subunits
(135kd) and two beta subunits (95kd); they linked by three
disulﬁde bonds. Alpha subunits are outside of cell; beta
subunits are embedded in membranes. The combination
of insulin and alpha subunits caused phosphorylation of
multiple tyrosine residues of beta subunits, which activated
protein tyrosine kinase (PTK) and triggered a series of cas-
cade ampliﬁcation reaction of phosphorylation and dephos-
phorylation to adjust the metabolism. PTPase (protein
tyrosine phosphatase) is the main negative regulatory factor
in insulin signaling pathways; it caused dephosphorylation
of insulin receptor and its substrate and weakened insulin
signals.
Possible mechanisms for hypoglycemic properties of
VOCCA and VOCCH are as follows: VOCCA and VOCCH
could inhibit the dephosphorylation activity of PTPase, so
dephosphorylationoftyrosinekinaseanddownstreamsignal
substrate will be inhibited. In this way, the action time of
insulin signal was prolonged, so VOCCA and VOCCH could
lower the blood sugar level (Figure 10).
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